While randomized phase III clinical trials are currently recruiting to evaluate the use of BRAF targeted therapy for stage IIC and III melanomas in the adjuvant setting as an alternative to interferon drugs, these treatments are not without the potential to develop some or all of the adverse side-effects of the BRAF targeted therapies (2). The gene discussed is BRAF; the disease is melanoma.